New rapid test could detect three infections at once

NCT ID NCT07563309

Recruiting now Diagnosis Sponsor: bioLytical Laboratories Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is testing a new rapid diagnostic device called TruPlex that can detect HIV, Hepatitis B, and Syphilis from a small blood sample. Researchers will enroll 1000 adults at risk for these infections to see how accurate and easy the test is to use in clinics and point-of-care settings. The goal is to provide a fast, reliable way to diagnose these diseases and help start treatment sooner.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: TruPlex HIV/HepB/Syphilis Rapid Test (a diagnostic device)
What this could lead to: If successful, this could provide a fast, reliable way to test for three infections at once, improving early detection and treatment.
What could go wrong: This is an early-stage study focused on device performance, not treatment. The test may not be as accurate as lab-based methods, and results depend on user training.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATITIS B INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatitis B virus infection HIV infectious disease syphilis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATITIS B INFECTION HIV 2 INFECTION HIV-1-INFECTION SYPHILIS INFECTION

Contacts and locations

Locations

Epicentre Health Research
RECRUITING

Durban, KwaZulu-Natal, 3650, South Africa
Epicentre Health Research (Cape Town)
RECRUITING

Cape Town, Western Cape, 7925, South Africa
Epicentre Health Research (Johannesburg)
RECRUITING

Johannesburg, Gauteng, 2193, South Africa

More trials for these conditions

Other studies related to the condition(s) this trial covers.